InnoCentive Posts $1 Million Seeker Challenge for Biomarker Discovery

InnoCentive announced today that Prize4Life, Inc., a non-profit
organization founded to accelerate Lou Gehrig's disease research, has
offered a $1 million incentive to help advance the treatment for
Amyotrophic Lateral Sclerosis. "This important challenge, identifying
an ALS 'biomarker,' is an effort to identify a specific measurement
for the disease that can aid in detection and response to therapy,"
said Jill A. Panetta, Ph.D., InnoCentive's Chief Scientific Officer.

"Valid biomarkers will enhance our understanding of the
pathological process in ALS and our ability to gauge treatment
efficacy," said Robert H. Brown, M.D., D.Phil. Brown is a member of
the Prize4Life Scientific Board, as well as founder and director of
the Day Neuromuscular Research Laboratory, director of the Muscular
Dystrophy Association Clinic at Massachusetts General Hospital, and
professor of neurology at Harvard Medical School. Brown added, "Such
markers can potentially speed up drug discovery protocols and
substantially shorten time and expense for treatment trials in ALS."

"We are honored to partner with Prize4Life to accelerate ALS
research allowing them to tap into our problem solving community of
more than 110,000 scientists," said Ali Hussein, InnoCentive's chief
marketing officer and vice president global markets. "Our network is
the fastest and most efficient way for research institutions to share
their breakthroughs with the business communities who can develop
these discoveries for the marketplace," added Hussein. "Prize4Life
posted this challenge on the InnoCentive Web site, recognizing that
this approach is an efficient way in which to gather a wide diversity
of ideas and scientific approaches in hopes of quickly solving this
significant disease," said Hussein.

Researchers and scientists interested in offering a solution for
the biomarker challenges must register on InnoCentive's Web site,
www.innocentive.com.

About Prize4Life

Prize4Life is a results-oriented nonprofit founded to accelerate
ALS (Lou Gehrig's disease) research by offering substantial prizes to
scientists who solve the most critical scientific problems preventing
the discovery of an effective ALS treatment. For additional
information on Prize4Life or to donate, please visit
www.prize4life.org.

About InnoCentive

InnoCentive is the first online forum that allows world-class
scientists and science-based companies to collaborate in a global
scientific community to achieve innovative solutions to complex
challenges. Companies including Dow AgroSciences, Eli Lilly and
Company, Procter & Gamble and others, which collectively spend
billions of dollars on R&D, post scientific problems confidentially on
the InnoCentive Web site where over 110,000 scientists and scientific
organizations in more than 175 countries can solve them. Scientists
who deliver solutions that best meet InnoCentive's challenge
requirements receive financial awards ranging up to and over $100,000.
To learn more and to register as an InnoCentive Solver, visit the
InnoCentive Web site at www.innocentive.com.